Trial Profile
Sanctura Muscarinic Receptor Antagonist Resists Transport (SMART-II) Trial.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 18 Aug 2012
Price :
$35
*
At a glance
- Drugs Trospium chloride (Primary) ; Oxybutynin
- Indications Overactive bladder
- Focus Pharmacodynamics; Pharmacokinetics
- Acronyms SMART-II
- Sponsors Allergan
- 15 Aug 2012 Actual end date (Mar 2011) added as reported by ClinicalTrials.gov.
- 02 May 2012 Results presented at the 2012 Annual Scientific Meeting of the American Geriatrics Society.
- 31 May 2011 Planned end date changed from 1 Jan 2011 to 1 Oct 2011 as reported by ClinicalTrials.gov.